{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:50:57Z","timestamp":1776505857821,"version":"3.51.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/maj.0b013e318256754f","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T06:49:53Z","timestamp":1345186193000},"page":"491-497","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of mTOR Inhibitor Therapy in Patients With Early-Stage Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"344","author":[{"given":"Qiang","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiayu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunxian","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6 suppl","key":"10.1097\/MAJ.0b013e318256754f_bb0005","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.transproceed.2009.06.097","article-title":"Mammalian target of rapamycin and autosomal dominant polycystic kidney disease","volume":"41","author":"W\u00fcthrich","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000254338","article-title":"Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy","volume":"32","author":"W\u00fcthrich","year":"2009","journal-title":"Kidney Blood Press Res"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00029330-200611020-00012","article-title":"Research on autosomal dominant polycystic kidney disease in China","volume":"119","author":"Dai","year":"2006","journal-title":"Chin Med J (Engl)"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0025","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/93.20.1517","article-title":"Rapamycin\u2019s resurrection: a new way to target the cancer cell cycle","volume":"93","author":"Garber","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pharmthera.2009.03.014","article-title":"Therapeutic role of sirolimus in non-transplant kidney disease","volume":"123","author":"Rangan","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0035","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1093\/ndt\/gfq527","article-title":"Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment","volume":"25","author":"Ponticelli","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/geno.1996.0206","article-title":"Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization","volume":"33","author":"Moore","year":"1996","journal-title":"Genomics."},{"key":"10.1097\/MAJ.0b013e318256754f_bb0050","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0055","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0060","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","article-title":"mTOR inhibitors in polycystic kidney disease","volume":"363","author":"Watnick","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0065","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1681\/ASN.2010030262","article-title":"Randomized intervention studies in human polycystic kidney and liver disease","volume":"21","author":"Schrier","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0075","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1093\/ndt\/gfp280","article-title":"Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease","volume":"24","author":"Serra","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0080","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0085","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0090","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0095","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.transproceed.2009.05.032","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study","volume":"41","author":"Soliman","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0105","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0110","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/ndt\/gfp129","article-title":"Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)","volume":"24","author":"Zafar","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1097\/MAJ.0b013e318256754f_bb0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915307928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915307928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T22:52:12Z","timestamp":1562107932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915307928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0002962915307928"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e318256754f","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}